Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Venous Thrombosis 2Venous Thromboembolism 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Venous Thormboembolism 1Thrombosis 1Small Cell Lung Carcinoma 1Pulmonary Embolism 1Colorectal Neoplasms 1Catheter-Related Infections 1Carcinoma, Pancreatic Ductal 1

Interventions

Paclitaxel 134Carboplatin 129Bevacizumab 86Gemcitabine 45pembrolizumab 37olaparib 33Cisplatin 30liposomal doxorubicin 29Docetaxel 29Cyclophosphamide 29Topotecan 28niraparib 27Taxes 20Etoposide 18Filgrastim 16Doxorubicin 16Immunoglobulin G 15Disulfides 15apatinib 12Letrozole 12Albumin-Bound Paclitaxel 12Drug Therapy 11fluzoparib 10fludarabine 10Specimen Handling 10Magnetic Resonance Spectroscopy 10Biopsy 10durvalumab 9Nivolumab 9pazopanib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Ovarian Neoplasms × Enoxaparin × Clear all
NCT03532139 2025-01-23

Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)

Beth Israel Deaconess Medical Center

Phase 2 Completed
24 enrolled
Gynecologic

Ovarian Neoplasms

NCT00908960 2017-12-19

MicroTEC

Dana-Farber Cancer Institute

Phase 2 Completed
70 enrolled 9 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡